Idarubicin-Loaded ONCOZENE Drug-Eluting Embolic Agents for Chemoembolization of Hepatocellular Carcinoma: In Vitro Loading and Release and In Vivo Pharmacokinetics

摘要: Abstract Purpose To present in vitro loading and release characteristics of idarubicin with ONCOZENE (CeloNova BioSciences, Inc, San Antonio, Texas) drug-eluting embolic (DEE) agents vivo pharmacokinetics data after transarterial chemoembolization idarubicin-loaded DEE patients hepatocellular carcinoma. Materials Methods Loading efficacy 100 µm DC Bead (Biocompatibles UK Ltd, Farnham, United Kingdom) 100–300 was monitored at 10, 20, 30 minutes time by high-pressure liquid chromatography. A T-apparatus used to monitor the from two types over 12 hours. Clinical 24-hour were recorded four unresectable Results Idarubicin > 99% 10 minutes. Time reach 75% plateau level 37 ± 6 for 170 19 both loaded mg/mL. After agents, three partial responses one complete response observed only asymptomatic grade 3 biologic adverse events. Median maximum concentration minutes, mean 4.9 µg/L 1.7. Mean area under concentration-time curve 0–24 hours equal 29.5 µg.h/L 20.5. Conclusions show promising results very fast ability, a favorable profile sustained during first 24 hours, encouraging safety responses. Histopathologic clinical studies are needed evaluate around tumor tissue confirm efficacy.